We are live on ! Find out more
TMO icon

Thermo Fisher Scientific

2,282 hedge funds and large institutions have $186B invested in Thermo Fisher Scientific in 2022 Q2 according to their latest regulatory filings, with 123 funds opening new positions, 824 increasing their positions, 969 reducing their positions, and 122 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more funds holding in top 10

Funds holding in top 10: 205253 (+48)

1% more first-time investments, than exits

New positions opened: 123 | Existing positions closed: 122

0.66% less ownership

Funds ownership: 88.3%87.64% (-0.66%)

1% less call options, than puts

Call options by funds: $1.07B | Put options by funds: $1.08B

1% less funds holding

Funds holding: 2,3152,282 (-33)

8% less capital invested

Capital invested by funds: $203B → $186B (-$17.1B)

15% less repeat investments, than reductions

Existing positions increased: 824 | Existing positions reduced: 969

Holders
2,282
Holders Change
-33
Holders Change %
-1.43%
% of All Funds
38.44%
Holding in Top 10
253
Holding in Top 10 Change
+48
Holding in Top 10 Change %
+23.41%
% of All Funds
4.26%
New
123
Increased
824
Reduced
969
Closed
122
Calls
$1.07B
Puts
$1.08B
Net Calls
-$11.4M
Net Calls Change
+$624M
Name Holding Trade Value Shares
Change
Change in
Stake
ADEF
326
Adams Diversified Equity Fund
Maryland
$37.3M
FAF
327
Fjarde Ap-fonden
Sweden
$37M -$13.2M -23,900 -26%
WIM
328
Waverton Investment Management
United Kingdom
$36.9M +$4.6M +8,350 +14%
ABC
329
Associated Banc-Corp
Wisconsin
$36.7M +$551K +1,001 +2%
SAM
330
Shell Asset Management
Netherlands
$36.4M +$2.77M +5,033 +8%
WA
331
WestEnd Advisors
North Carolina
$36M +$36.5M +66,301 New
PGFC
332
Peapack-Gladstone Financial Corp
New Jersey
$36M -$396K -720 -1%
SRC
333
Shufro Rose & Co
New York
$35.7M -$2M -3,641 -5%
II
334
IFM Investors
Australia
$35.5M +$2.14M +3,882 +6%
EOJOAM
335
E. Ohman J:or Asset Management
Sweden
$35.4M -$11.4M -20,800 -24%
SCM
336
Snowhook Capital Management
New York
$34.6M +$84.2K +153 +0.2%
PHS
337
PFM Health Sciences
California
$33.8M
UCFA
338
United Capital Financial Advisors
Texas
$33.6M +$2.58M +4,688 +8%
BA
339
Bridgewater Associates
Connecticut
$33.5M -$40.8M -74,057 -55%
NYLIM
340
New York Life Investment Management
New York
$33.4M +$33.8M +61,460 New
ProShare Advisors
341
ProShare Advisors
Maryland
$33.4M -$13.2M -24,027 -28%
WSFS
342
Wilmington Savings Fund Society
Delaware
$33.1M -$1.3M -2,361 -4%
TAF
343
Tredje AP-fonden
Sweden
$33M
MLL
344
Moody Lynn & Lieberson
Massachusetts
$33M -$3.33M -6,042 -9%
BIM
345
Bridges Investment Management
Nebraska
$32.7M -$87.5K -159 -0.3%
AAP
346
Aristotle Atlantic Partners
Florida
$32.5M +$828K +1,505 +3%
BTCPP
347
Border to Coast Pensions Partnership
United Kingdom
$32.3M +$4.3M +7,811 +15%
EDRH
348
Edmond de Rothschild Holding
Switzerland
$32.2M -$1.86M -3,386 -5%
Daiwa Securities Group
349
Daiwa Securities Group
Japan
$32.1M -$1.6M -2,900 -5%
IMPI
350
Ilmarinen Mutual Pension Insurance
Finland
$31.8M

TMO Hedge Fund Activity: Q2 2022 in Review

2,282 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Thermo Fisher Scientific (TMO) for Q2 2022, worth a combined $186B — down 8.5% from $203B a quarter earlier.

Buyers outnumbered sellers: 123 funds opened new TMO positions and 122 closed out — a net gain of 1 holder — while 824 added to existing stakes and 969 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $896M. The largest seller was T. Rowe Price Associates, cutting an estimated $982M.

  • 2,282 institutional investors held Thermo Fisher Scientific (TMO) as of Q2 2022, down from 2,315 in Q1 2022.
  • Funds reported $186B of Thermo Fisher Scientific stock for Q2 2022, down 8.5% quarter-over-quarter.
  • 123 funds opened new Thermo Fisher Scientific positions in Q2 2022 and 122 closed out, a net change of +1 holder.
  • The largest Thermo Fisher Scientific buyer in Q2 2022 was Morgan Stanley, an estimated $896M added.
  • The largest Thermo Fisher Scientific seller in Q2 2022 was T. Rowe Price Associates, an estimated $982M sold.

Based on aggregated 13F filings for Q2 2022.